專長學科
癌症藥物治療、藥物分析、藥物化學
經歷
國軍金門醫院 藥劑官(0911225-0930118)
署立桃園醫院 藥師(0930201-0930430)
承安醫院籌備處 員工(0930501-0930731)
承安醫院 藥師(0930801-0940831)
三軍總醫院臨床藥學部調劑科住院藥局 藥師(0940902-0970616)
三軍總醫院臨床藥學部臨藥科調製組 藥師(0970916-1100731)
三軍總醫院臨床藥學部臨藥科調製組 副組長(1030501-1050131)
三軍總醫院臨床藥學部臨藥科 總藥師 (1100801-迄今)
營養治療委員會委員(0990101-0991231)
營養治療審議會委員(1040601-1041231)
研究著作
1.Liu CT, Kao LT, Shih JH, Chien WC, Chiu CH, Ma KH, Huang YS, Cheng CY, Shiue CY, Li IH. The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study. Eur J Pharmacol. 2019 Nov 5;862:172639. doi: 10.1016/j.ejphar.2019.172639. Epub 2019 Sep 3. PMID: 31491406.
2.Liu CT, Huang YS, Chen HC, Ma KH, Wang CH, Chiu CH, Shih JH, Kang HH, Shiue CY, Li IH. Evaluation of brain SERT with 4-[18F]-ADAM/micro-PET and hearing protective effects of dextromethorphan in hearing loss rat model. Toxicol Appl Pharmacol. 2019 Sep 1;378:114604. doi: 10.1016/j.taap.2019.114604. Epub 2019 May 30. PMID: 31153898.
3.Won SJ, Liu CT, Tsao LT, Weng JR, Ko HH, Wang JP, Lin CN. Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. Eur J Med Chem. 2005 Jan;40(1):103-12. doi: 10.1016/j.ejmech.2004.09.006. PMID: 15642415.
4.Ko HH, Hsieh HK, Liu CT, Lin HC, Teng CM, Lin CN. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation. J Pharm Pharmacol. 2004 Oct;56(10):1333-7. doi: 10.1211/0022357044247. PMID: 15482650.
5.Ko HH, Tsao LT, Yu KL, Liu CT, Wang JP, Lin CN. Structure-activity relationship studies on chalcone derivatives. the potent inhibition of chemical mediators release. Bioorg Med Chem. 2003 Jan 2;11(1):105-11. doi: 10.1016/s0968-0896(02)00312-7. PMID: 12467713.
得獎事蹟
聯絡分機
E-mail